Management of Severe Hypertension Without Acute End‑Organ Damage

1. Immediate Assessment and Determination of Hypertensive Emergency

• Patients with systolic/diastolic BP ≈ 180/100 mmHg but no neurologic deficits, papilledema, or acute organ dysfunction do not meet criteria for hypertensive emergency and can be managed without intravenous therapy. 3
• An isolated headache, even when severe, is not sufficient to diagnose hypertensive encephalopathy in the absence of neurologic signs. 5
• When BP falls to ~160/80 mmHg after a short‑acting agent (e.g., clonidine), the response indicates adequate treatment and further IV antihypertensives are unnecessary. 5

2. Choice of Antihypertensive Agents

2.1 First‑Line Oral Regimen (International Society of Hypertension 2020)

• A combination of an angiotensin‑receptor blocker (ARB) plus a calcium‑channel blocker (CCB) is recommended as first‑line therapy for severe hypertension without acute HMOD. 1
• Restarting amlodipine 10 mg once daily together with losartan 50 mg once daily is the logical approach when this regimen previously achieved target BP. 1

2.2 Role of Clonidine

• Clonidine should be avoided for long‑term hypertension management and reserved only as a last‑resort option after failure of other agents. 1
• Additional clonidine doses (total ≈ 225 µg) are excessive in acute settings and should be discontinued. 5

3. Stepwise Escalation When BP Remains Uncontrolled

• If oral therapy with ARB + CCB does not achieve the desired reduction (≥ 20/10 mmHg, aiming for < 140/90 mmHg), add hydrochlorothiazide 12.5 mg daily. 1
• If still uncontrolled, increase hydrochlorothiazide to 25 mg daily. 1
• For resistant hypertension, add spironolactone 25 mg daily as the preferred fourth‑line agent. 7
• Alternative fourth‑line options include amiloride, doxazosin, eplerenone, or a beta‑blocker. 1

4. Headache Management in the Context of Severe Hypertension

• A moderate‑to‑severe headache (e.g., 7/10 intensity) is likely secondary to elevated BP and should be monitored while BP is being lowered. 3
• Analgesia (e.g., tramadol) may be administered for pain control. 7
• Persistent or worsening headache despite adequate BP control warrants neuroimaging to exclude secondary causes. 3

5. Monitoring and Follow‑Up

• Short‑Term: Observe the patient for at least 2 hours after restarting amlodipine to assess efficacy and safety; re‑measure BP every 30–60 minutes initially, then every 4–6 hours once stable. 5
• Medium‑Term: Aim for BP control within 3 months with targets < 140/90 mmHg (or < 130/80 mmHg if tolerated). Schedule a follow‑up visit within 1–2 weeks and consider home BP monitoring to verify office readings. 1

6. Critical Pitfalls to Avoid (European Society of Cardiology Guidance)

• Do not pursue rapid BP reduction in the absence of acute HMOD, as this may cause ischemic complications. 5
• IV antihypertensives should be reserved for true hypertensive emergencies. 3
• Short‑acting nifedipine should be avoided because of unpredictable rapid BP drops. 5

7. Medication Adherence and Secondary Hypertension Screening

• Investigate reasons for prior discontinuation of amlodipine (e.g., side effects, non‑adherence) and address barriers such as cost or regimen complexity. 1
• Consider single‑pill combination formulations to improve adherence when multiple agents are required. 1
• Secondary causes are identified in 20–40 % of patients with severe or malignant hypertension; evaluation should be pursued if BP remains uncontrolled despite appropriate therapy. 3